Publication: A double-blinded randomized controlled trial of silymarin for the prevention of antituberculosis drug-induced liver injury
Issued Date
2015-09-23
Resource Type
ISSN
14726882
Other identifier(s)
2-s2.0-84960403851
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
BMC Complementary and Alternative Medicine. Vol.15, No.1 (2015)
Suggested Citation
Chote Luangchosiri, Ammarin Thakkinstian, Sermsiri Chitphuk, Wasana Stitchantrakul, Supanna Petraksa, Abhasnee Sobhonslidsuk A double-blinded randomized controlled trial of silymarin for the prevention of antituberculosis drug-induced liver injury. BMC Complementary and Alternative Medicine. Vol.15, No.1 (2015). doi:10.1186/s12906-015-0861-7 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/36321
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
A double-blinded randomized controlled trial of silymarin for the prevention of antituberculosis drug-induced liver injury
Other Contributor(s)
Abstract
© 2015 Luangchosiri et al. Background: Hepatitis is a common adverse effect of antituberculosis drugs. Silymarin prevented drug-induced hepatoxicity in animals with anti-oxidative mechanisms but its effect in human has been unknown. We aimed to evaluate the efficacy of silymarin for preventing antituberculosis-drug induced liver injury (antiTB-DILI) in patients with tuberculosis. Methods: A double-blind randomized placebo-controlled trial was performed. Tuberculosis patients were randomly allocated to receive placebo or silymarin. The outcomes of interests were antiTB-DILI and the maximum liver enzymes at week 4. Antioxidative enzymes (i.e., superoxide dismutase (SOD), glutathione and malondialdehyde assays) were assessed. The risks of antiTB-DILI between the two groups were compared. A number need to treat was estimated. Results: A total of 55 out of 70 expected numbers of patients were enrolled. There were 1/27 (3.7 %) and 9/28 (32.1 %) patients who developed antiTB-DILI in the silymarin and the placebo groups. Risk reduction was 0.28 (0.10, 0.47), i.e., receiving silymarin was 28 % at lower risk for antiTB-DILI than placebo. This led to prevention of 28 patients from being antiTB-DILI among 100 treated patients. Median (IQR) of ALT levels at week 4 in the placebo and the silymarin group were 35.0 (15, 415) IU/L and 31.5 (20, 184) IU/L (p = 0.455). The decline of SOD level at week 4 in the silymarin group was less than the placebo group (p < 0.027). Conclusions: Silymarin reduced the incidence of antiTB-DILI. The benefit of silymarin may be explained from superoxide dismutase restoration. Larger clinical trials are required to confirm the result of our small study [Clinicaltrials.Gov Identifier Nct01800487].